Press Release HAG EUNETHTA21 – Professor Michael Barry, Director of the National Centre for Pharmacoeconomics joins the inaugural Heads of Agency Group.

http://www.ncpe.ie/research/covid-19/

The NCPE recommend that darolutamide (Nubeqa®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

The NCPE recommends that venetoclax in combination with obinutuzumab be considered for reimbursement.*

The NCPE recommends that risankizumab (Skyrizi®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Following NCPE assessment of the Applicant’s submission, cost effectiveness of ruxolitinib (Jakavi®) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement unless cost-effectiveness can be improved relative to existing treatments.

The NCPE recommends that Sativex® not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

The NCPE recommends that nintedanib (Ofev®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

The NCPE recommends that avelumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

The Beneluxa collaboration has issued a joint statement with the Nordic Pharmaceutical Forum.